Achaogen | Evaluate

November 20, 2018

Patience is a virtue for big pharma buyers

For biotechs nearing regulatory approval the key is to sell before launch. For buyers, playing the waiting game is a better strategy.

August 13, 2018

After Alnylam’s solo maiden launch, here comes the tricky bit

Alnylam has secured its first approval, but history suggests that launch will be far from easy.

June 29, 2018

Snippet roundup: Approvals for Array and Dermira, but Achaogen falls short

June 08, 2018

Upcoming events – Array and Achaogen head to US regulators

It's all about the label for plazomicin, and Array’s Braf-Mek project stacks up well against the competition.

May 04, 2018

Snippet roundup: The good times roll for Moderna, but Mallinckrodt and Smith & Nephew flag

April 20, 2018

Upcoming events – Panel decisions due for Achaogen and Akcea

February 14, 2018

Intravenous inferiority makes it two failures for Tetraphase

November 30, 2017

Medicines Company shows that there’s money in antibiotics after all

April 06, 2017

Mid-cap biopharma stocks pick up in the first quarter

December 13, 2016

Epic antibiotic data could spur interest in Achaogen

December 02, 2016

Upcoming events – Achaogen’s antibiotic and Nektar tries out its opioid again

Load More